The collaborations will provide Illumina's customers with workflows for genomic disease characterization and spatial mapping.

SPOT-Met (Weill Cornell Medicine): SPOT-Met (Spatial Predictors Of Tropism and Metastasis), a 1,000-tumor colorectal cancer program described as the world's largest colorectal cancer multimodal ...

Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, ...

We combine advanced technologies such as spatial transcriptomics, multiplexed imaging, and in situ sequencing to map cellular components in their native tissue context. Obtain high-resolution data ...

"Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms," said Steve Barnard, PhD, chief technology officer of Illumina. "Illumina spatial ...

A new spatial transcriptomic technology captures RNA patterns without requiring expensive imaging ...

Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.

Spatial transcriptomics is a technique that provides information about gene expression patterns within intact tissues. This technology employs various methodologies, including in situ sequencing (ISS) ...

Takara Bio USA, Inc. ("Takara Bio USA"), a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), today announced a series of updates to its spatial biology product portfolio, extending its ...

Spatial ribonucleic acid (RNA) transcriptomics measures gene expression while preserving each molecule’s coordinates in intact tissue, tying transcripts to histology and local microenvironments.